A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: 14C-PF-06826647-LR 600 mg PO; Drug: PF-06826647 600 mg PO; Drug: 14C-PF-06826647 100 ug IV

• Registration Number: NCT04591262
• Lead Sponsor: Pfizer

Brief Summary

The purpose of the study is to determine the metabolism and excretion following a single oral administration of 14C-PF-06826647-LR (14C labelled PF-06826647 with lower radioactivity per mass unit) in fed conditions. This information will enable assessment of clearance mechanisms of PF-06826647 as well as identify metabolites. In addition, this study will determine absolute bioavailability of PF-06826647 and understand intravenous (IV) pharmacokinetic (PK).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-09-09
• Study First Submitted QC: 2020-10-13
• Study First Posted: 2020-10-19
• Study Start: 2020-11-10
• Primary Completion: 2021-01-28
• Study Completion: 2021-01-28
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-17
• Last Update Posted: 2021-02-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 6

Inclusion Criteria

• Healthy Male participants must be 18 to 55 years of age, inclusive.
• Male participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, including BP and pulse rate measurement, laboratory tests, and 12 lead ECG.
• Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
• BMI of 17.5 to 30 kg/m2; and a total body weight >50 kg (110 lb).

Read More

Exclusion Criteria

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
• Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
• History of irregular bowel movements including irritable bowel syndrome or frequent episodes of diarrhea or constipation defined by less than 1 bowel movement on average per 2 days or lactose intolerance.
• Participants who currently use or have formerly used (within 6 months of dosing) tobacco or nicotine containing products.
• Total 14C radioactivity measured in plasma exceeding 11 mBq/mL.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
PF-06826647 600 mg PO>PF-06826647 600 mg PO+100 ug IV	14C-PF-06826647 100 ug IV	PF-06826647 600 mg single dose in Period 1 followed by PF-06826647 600 mg PO and IV infusion of 100 ug of PF-06826647 in Period 2.
PF-06826647 600 mg PO>PF-06826647 600 mg PO+100 ug IV	PF-06826647 600 mg PO	PF-06826647 600 mg single dose in Period 1 followed by PF-06826647 600 mg PO and IV infusion of 100 ug of PF-06826647 in Period 2.
PF-06826647 600 mg PO>PF-06826647 600 mg PO+100 ug IV	14C-PF-06826647-LR 600 mg PO	PF-06826647 600 mg single dose in Period 1 followed by PF-06826647 600 mg PO and IV infusion of 100 ug of PF-06826647 in Period 2.

Primary Outcome Measures

Name	Time	Method
Total radioactivity in urine and feces together expressed as percent of total oral radioactive dose	Up to Day 14

Secondary Outcome Measures

Name	Time	Method
Number of participants with abnormal ECG	Up to Day 28	Criteria for ECG abnormalities: maximum PR interval \>=300 milliseconds (msec) and maximum increase PR interval increase from baseline (IFB): percent change (Pctchg) \>=25 percent (%) for baseline value of \>200 msec and Pctchg\>=50% for baseline value of \<=200 msec for PR interval, maximum QRS interval \>=140 msec and a maximum IFB: Pctchg\>=50%, maximum QTCF interval (Fridericia's Correction) of 450 msec to \<480 msec, 480 msec to \<500 msec or \>=500 msec and a maximum change of \<=30change\<60 or \>=60 msec from baseline.
Number of Participants With Clinically Significant Change From Baseline in Vital Signs	Up to Day 28	Following parameters were analyzed for examination of vital signs: systolic and diastolic blood pressure, respiratory rate, radial pulse and body temperature.
The ratio of dose normalized AUCinf of PF-06826647 and 14C-PF-06826647	0 hours to 96 hours	The ratio of dose normalized AUCinf of PF-06826647 (LCMS) and 14C-PF-06826647 (AMS). AUCinf= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time . It is obtained from AUC (0 - t) plus AUC (t - ∞).
Number of Participants With Laboratory Test Values of Potential Clinical Importance	Up to Day 28	Pre-defined criteria were established for each laboratory test to define the values that would be identified as of potential clinical importance.

Trial Locations

Locations (2)

PRA Health Sciences; 🇳🇱 Groningen, Netherlands

PRA Health Sciences Utrecht; 🇳🇱 Utrecht, Netherlands